Moderna, Inc. (NASDAQ:MRNA) President Sells $24,482.82 in Stock

Moderna, Inc. (NASDAQ:MRNA) President Stephen Hoge sold 318 shares of Moderna stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $76.99, for a total transaction of $24,482.82. Following the transaction, the president now directly owns 1,443,002 shares of the company’s stock, valued at $111,096,723.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website.

Stephen Hoge also recently made the following trade(s):

• On Thursday, August 29th, Stephen Hoge sold 300 shares of Moderna stock. The stock was sold at an average price of $78.03, for a total transaction of $23,409.00.
• On Monday, August 12th, Stephen Hoge sold 254 shares of Moderna stock. The shares were sold at an average price of $84.10, for a total transaction of $21,361.40.
• On Monday, July 15th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $121.12, for a total value of $1,816,800.00.
• On Monday, June 17th, Stephen Hoge sold 15,000 shares of Moderna stock. The stock was sold at an average price of $138.16, for a total value of $2,072,400.00.

Moderna Trading Down 0.7 %

Shares of MRNA opened at $72.89 on Friday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 3.92 and a current ratio of 4.09. Moderna, Inc. has a 52-week low of $62.55 and a 52-week high of $170.47. The firm has a market cap of $27.93 billion, a price-to-earnings ratio of -4.65 and a beta of 1.67. The business’s fifty day moving average is $100.18 and its 200-day moving average is $112.42.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, August 1st. The company reported ($3.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.47) by $0.14. The firm had revenue of $241.00 million for the quarter, compared to analysts’ expectations of $128.41 million. Moderna had a negative return on equity of 21.35% and a negative net margin of 116.18%. The business’s revenue for the quarter was down 29.9% on a year-over-year basis. During the same quarter in the previous year, the business posted ($3.62) earnings per share. Equities analysts anticipate that Moderna, Inc. will post -9.52 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on MRNA. JPMorgan Chase & Co. decreased their price objective on Moderna from $96.00 to $88.00 and set a “neutral” rating on the stock in a report on Thursday, August 15th. Piper Sandler restated an “overweight” rating and issued a $157.00 price target (down from $214.00) on shares of Moderna in a research note on Friday, August 2nd. Evercore ISI reiterated an “in-line” rating and issued a $120.00 price objective on shares of Moderna in a research note on Thursday, June 27th. Hsbc Global Res upgraded shares of Moderna from a “moderate sell” rating to a “hold” rating in a research report on Wednesday, August 28th. Finally, Oppenheimer lifted their price target on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a research report on Wednesday, June 12th. Ten research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $123.79.

Institutional Investors Weigh In On Moderna

Several hedge funds and other institutional investors have recently made changes to their positions in MRNA. Ashton Thomas Private Wealth LLC acquired a new stake in Moderna in the second quarter valued at approximately $26,000. Ogorek Anthony Joseph NY ADV bought a new position in shares of Moderna in the 4th quarter valued at $27,000. Cedar Wealth Management LLC boosted its holdings in shares of Moderna by 45.0% during the 1st quarter. Cedar Wealth Management LLC now owns 290 shares of the company’s stock valued at $31,000 after acquiring an additional 90 shares in the last quarter. Westside Investment Management Inc. bought a new stake in Moderna during the 1st quarter worth $32,000. Finally, Family Firm Inc. bought a new stake in Moderna during the 2nd quarter worth $33,000. 75.33% of the stock is owned by institutional investors.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.